ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
ProKidney Corp. reports that CEO and director Bruce Culleton acquired 500,000 performance-based options under an award originally granted December 3, 2023. On November 2, 2026, the board certified that the performance goal was achieved at 100%. The options cover Class A Common Stock, have a $1.69 exercise price and expire December 3, 2033.
Twenty-five percent vested on November 2, 2026; the remaining 75% vests in three 125,000-share installments on February 15, May 15 and August 15, 2027.
ProKidney Corp. Chief Regulatory Officer Darin J. Weber converted 200,000 shares of Class B Common Stock and 200,000 Common Units into 200,000 shares of Class A Common Stock on October 28, 2026. The paired securities may be exchanged one-for-one, subject to limitations in the applicable agreements. The reported post-transaction positions were 202,283 Class B shares, 202,283 Common Units, and 200,000 Class A shares.
ProKidney Corp. entered into an at-the-market sales agreement with Jefferies LLC under which it may offer and sell Class A common stock up to a maximum aggregate offering price of $200 million, once its Form S-3 registration statement is effective. Permitted sales include ordinary brokerage transactions, transactions through a market maker or other market venue, over-the-counter sales, and privately negotiated transactions.
ProKidney has no obligation to sell shares and may suspend the offering at any time. It made no assurances that the registration statement will become or remain effective. Jefferies is entitled to compensation of up to 3.0% of gross offering proceeds from shares sold through it; ProKidney will also reimburse certain specified expenses.
ProKidney Corp. has filed a shelf registration for offerings of up to $650,000,000, with sales permitted only after the registration statement becomes effective. After effectiveness, ProKidney may sell up to $200,000,000 of Class A common stock through Jefferies from time to time in an at-the-market offering under a sales agreement; this capacity is included within—not added to—the $650,000,000 shelf. The shelf may be used for Class A common stock, preferred stock, debt securities, warrants, rights or units.
ProKidney intends to use net proceeds, if any, for clinical-trial costs and research and development, continued investment in its drug development platform, pre-commercial and commercial activities including a commercial manufacturing facility, and general corporate purposes, unless an applicable prospectus supplement indicates otherwise. The company describes itself as a late clinical-stage biotechnology company developing rilparencel, which is being evaluated in Phase 3 REGEN-006 (PROACT 1). ProKidney says it has no product candidates approved for sale and has generated no revenue from product sales.
PROKIDNEY CORP. (PROK) director Brian J. G. Pereira reported six sales of Class A Common Stock over August 18–20, 2026, totaling 757,164 shares. Sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at weighted average prices between $1.345 and $1.50 per share in open market or private transactions.
ProKidney Corp. (PROK) is the issuer for a notice of proposed sale of restricted or control securities under Rule 144. Director Brian Pereira, through the Brian Pereira 2012 Trust, has filed to sell 675,235 shares of ProKidney common stock that were acquired on January 17, 2022 for cash. Merrill Lynch Pierce Fenner & Smith is listed as the broker, and a prior sale of 27,826 common shares on August 18, 2026 for $38,154.23 is also reported.
ProKidney Corp. (PROK) received a Rule 144 notice indicating that director Brian Pereira plans to sell common stock. The notice lists a planned sale of 114,000 shares of common stock of ProKidney through Merrill Lynch Pierce Fenner and Smith on NASDAQ. It also discloses that a related holder, the Brian Pereira 2012 Irrevocable Trust, has sold 229,338 shares of ProKidney common stock over the past three months for $314,462.14.
Morgan Stanley and an affiliate reported their current ownership in ProKidney Corp. Class A common stock on a Schedule 13G/A amendment. Morgan Stanley reported aggregate beneficial ownership of 9,653,756 shares with 4.7% of the class, all through shared voting and dispositive power. Morgan Stanley Investment Management Inc. reported beneficial ownership of 9,642,992 shares, also representing 4.7% of the class, with no sole voting or dispositive power. Both entities stated that, as of the reporting date, each has ceased to be the beneficial owner of more than five percent of this class of securities.
ProKidney Corp. reported second quarter 2026 results and progress on its lead cell therapy program rilparencel for advanced chronic kidney disease with type 2 diabetes. Enrollment was completed for the Phase 3 PROACT 1 accelerated approval efficacy analysis, expected to include about 320 patients using annualized eGFR slope as a surrogate endpoint, with topline results anticipated in Q2 2027. Full enrollment of approximately 470 patients for the confirmatory time-to-event analysis is targeted for the second half of 2026, with topline results anticipated in the second half of 2029.
ProKidney ended Q2 2026 with $181.6 million in cash, cash equivalents and marketable securities, which the company expects will fund operations into mid-2027. For the quarter, research and development expenses were $36.1 million and general and administrative expenses were $12.4 million. Net loss before noncontrolling interest was $46.4 million, and net loss available to Class A common stockholders was $28.4 million, or $0.15 per basic and diluted share. Net cash used in operating activities for the first six months of 2026 was $82.1 million.
The company strengthened its leadership by appointing Kenneth Locke as Chief Technical Officer, bringing more than 25 years of R&D, CMC and supply chain experience as ProKidney advances toward potential regulatory and commercial milestones for rilparencel.
ProKidney Corp., a late-clinical-stage biotech developing the autologous cell therapy rilparencel for advanced diabetic CKD, reported continued operating losses and a strained liquidity position for the quarter and six months ended June 30, 2026.
For the first half of 2026, revenue from building lease income was $0.4 million, while operating expenses reached $93.7 million, driven mainly by research and development of $69.9 million and general and administrative costs of $23.7 million. Net loss before noncontrolling interest was $89.1 million, compared with $74.9 million a year earlier, and net loss attributable to Class A shareholders was $48.5 million, or $0.29 per share.
Cash and cash equivalents plus marketable securities totaled $181.6 million at June 30, 2026, down from $270.0 million at year-end 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern, as existing liquidity is not expected to fund obligations for 12 months following the August 10, 2026 filing date without additional financing or strategic arrangements. The Phase 3 PROACT 1 study has completed enrollment for patients contributing to the accelerated-approval surrogate endpoint, with topline eGFR slope data expected in the second quarter of 2027.